Arbutus CSO Michael Sofia to retire Dec 31, 2024; no successor named yet.

Arbutus Biopharma Corp

Dr. Michael Sofia, co-founder and Chief Scientific Officer, notified retirement effective December 31, 2024.
Sofia is a Lasker award-winning antiviral drug discovery scientist with 38-year career.
Interim CEO Michael McElhaugh thanked Sofia for contributions to HBV functional cure development.
No replacement for CSO role announced; company continues clinical development.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michael Sofia

Chief Scientific Officer

ABUS · Arbutus Biopharma Corp

Effective: 2024-12-31
Filed: May 2, 2024, 7:59 PM ET

On May 1, 2024, Dr. Michael Sofia notified Arbutus Biopharma Corporation (the “Company”) of his retirement as Chief Scientific Officer of the Company, effective December 31, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Sofia departed as Chief Scientific Officer at Arbutus Biopharma Corp.

Action: notified retirement
Role: Chief Scientific Officer

Exact text from the filing

On May 1, 2024, Dr. Michael Sofia notified Arbutus Biopharma Corporation (the “Company”) of his retirement as Chief Scientific Officer of the Company, effective December 31, 2024.

View on SEC.gov

Arbutus Biopharma Corp filing history →

Source: SEC EDGAR

accession 0001171843-24-002452

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.